HHL HARVEST HEALTHCARE LEADERS INCM ETF CLASS A UNITS
- 8.640
- -0.010-0.12%
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Looking Into Danaher's Recent Short Interest
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Thermo Fisher Plant Making Astra/ Sanofi RSV Drug Reportedly Breached FDA Rules
WHO Approves First Mpox Diagnostic Test for Emergency Use
US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, with 'substitute' manufacturer Hims & Hers plunging more than 10% during trading.
FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.
Wells Fargo's 'Core' Stocks: GOOGL, HD, KO, and More
Wells Fargo's 'Value Equity' Stocks: VZ, AZO, KR, and More
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Eli Lilly Analyst Ratings
BofA's Top 10 Growth Stocks for October
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
4 Stocks to Watch on Thursday: STZ, LLY and More
U.S. Tweaks 2025 Medicare Price Negotiation Process
Peering Into Medtronic's Recent Short Interest
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges